autologous dendritic cell vaccine + nivolumab

This drug is a combination therapy comprised of an **autologous dendritic cell vaccine** (personalized for each patient using their own dendritic cells, often pulsed or loaded with tumor lysate antigens or neoantigens) and **nivolumab**, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). The dendritic cell vaccine aims to prime and activate the patient’s T cells to recognize and attack tumor cells, while nivolumab blocks immunosuppressive signaling via PD-1, preventing tumor immune escape and sustaining T-cell mediated anti-tumor response. This combination is under development for various cancers, including glioblastoma, ovarian cancer, and pancreatic adenocarcinoma, with reported evidence of improved anti-tumor responses and survival outcomes in clinical trials and case studies[1][3][5][7][9].

Other names

autologous dendritic cell vaccine + nivolumab